Medication-related osteonecrosis of the jaw in a cancer patient receiving lenvatinib.
|
| Abstract |
Medication-related osteonecrosis of the jaw (MRONJ) is an adverse drug reaction that affects the mandible and maxilla of patients exposed to bone-targeting agents such as anti-resorptive and anti-angiogenic agents. Several MRONJ cases have been reported after dental extractions in patients under treatment with anti-angiogenic agents, including receptor activator of nuclear factor κB ligand (RANKL) inhibitor, anti-vascular endothelial growth factor (anti-VEGF) monoclonal antibody, mammalian target of rapamycin (mTOR) inhibitors, and tyrosine kinase inhibitors (TKIs). The aim of this article was to describe an original case of lenvatinib-related osteonecrosis of the jaw in a patient affected by thyroid cancer. A 58-year-old man diagnosed with Hurthle cell thyroid cancer, who was undergoing treatment with lenvatinib, developed maxillary osteonecrosis after a dental extraction. No other concomitant local or systemic risk factors for MRONJ were present. With new cancer therapies applied every year, it is important to note this novel case of lenvatinib osteonecrosis of the jaw in a patient undergoing cancer treatment.
|
|---|---|
| Authors | R Mauceri, V Panzarella, I Morreale, G Campisi |
| Journal | International journal of oral and maxillofacial surgery (Int J Oral Maxillofac Surg) Vol. 48 Issue 12 Pg. 1530-1532 (Dec 2019) ISSN: 1399-0020 [Electronic] Denmark |
| PMID | 31378564 (Publication Type: Journal Article) |
| Copyright | Copyright © 2019 The Authors. Published by Elsevier Ltd.. All rights reserved. |
| Chemical References |
|
| Topics |
|
Join CureHunter, for free Research Interface BASIC access!
Realize the full power of the drug-disease research graph!